Frontiers in Endocrinology

Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data

By Ying Chen, Xueping Wang, Jingjuan Wang, Gaiping Ma

Figure 1 from Frontiers in Endocrinology — Figure 1. Chen et al.

Meta-analysis of observational studiesInterventions

452,763 participants, declared no competing interests

The paper

Ying Chen, Xueping Wang, Jingjuan Wang, Gaiping Ma

Army Medical University

Frontiers in Endocrinology, 13 Aug 2026

doi.org/10.3389/fendo.2026.1849318 PubMed 42661791

Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes